Revelation Biosciences, Inc.

REVBNASDAQHealthcare● Active

$1.01

+$0.02(+2.02%)

Market Cap$3947504

P/E Ratio—

52W High$12.88

52W Low$0.875

Avg Volume71K

Open$1.01

Beta-0.08

Free Cash Flow Financials Revenue

Revelation Biosciences, Inc. (REVB) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

REVB · free cash flow · updated Jun 9, 2026

Core FCF metrics

REVB · FCF · TTM · margin & CAGR

Free cash flow was −$8.3M for FY2025 (fiscal year ending 2025-12-31), up 54.9% year-over-year

FY2025 Free Cash Flow−$8.3M▲ +54.9% YoY

Trailing 12M (TTM)−$8.8Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

REVB · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$8.3M(0M)−$8.3M▲ +54.9%—

FY2024−$18.3M(0M)−$18.3M▼ 151.7%—

FY2023−$7.3M(0M)−$7.3M▲ +35.1%—

FY2022−$11.2M(0M)−$11.2M▲ +0.0%—

FY2021−$11.1M(0M)−$11.2M▼ 5118.1%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

REVB · P/FCF · FCF yield · FCF per share

Revelation Biosciences, Inc. (REVB) reported negative free cash flow of −$0.01B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

REVB · cash flow statement · operating / investing / financing

For FY2025, Revelation Biosciences, Inc. generated −$8.3M in operating cash flow and spent 0M in capital expenditures, yielding −$8.3M in free cash flow.

Operating Activities

−$8.3M

Cash from core business operations

2025-12-31

Investing Activities

+$0.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$12.5M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$8.3M) − |CapEx| (0M) = FCF (−$8.3M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

REVB vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Revelation Biosciences, Inc.YOU

REVB

−$8.3M+54.9%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Revelation Biosciences, Inc. (REVB) reported free cash flow of −$8.3M for FY2025 (fiscal year ending 2025-12-31), up 54.9% year-over-year.

Revelation Biosciences, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 7 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

REVB free cash flow · 8 questions

Revelation Biosciences, Inc. free cash flow was −$8.3M for FY2025, up 54.9% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$8.8M.

REVB free cash flowREVB FCFREVB FCF 2025REVB free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Revelation Biosciences, Inc. · Revelation Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026